Featured Trial
Our review committee has reviewed this trial and it meets our criteria for going above and beyond. Learn more about featured trials.
Clinical Trial Goal
To find out if linvoseltamab is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have been treated with lenalidomide
- Do not have any of the following:
- Plasma cell leukemia
- POEMS syndrome
- Waldenstrom macroglobulinemia
- Have not been treated with elotuzumab or pomalidomide. Your doctor can tell you this
- Have not had an autologous (your own cells) blood or marrow transplant (BMT) in the last 3 months
- Have not had an allogeneic (cells from a donor) BMT in the last 6 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Dexamethasone is a drug that reduces inflammation.
Elotuzumab is a monoclonal antibody that targets SLAMF7 in some cancer cells.
Linvoseltamab is a bispecific antibody that targets BCMA and CD3 in certain cells.
Pomalidomide is a drug that blocks the growth of cancer cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
Elotuzumab is a monoclonal antibody that targets SLAMF7 in some cancer cells.
Linvoseltamab is a bispecific antibody that targets BCMA and CD3 in certain cells.
Pomalidomide is a drug that blocks the growth of cancer cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
- Group 1 – Linvoseltamab
- Group 2 – Dexamethasone, elotuzumab and pomalidomide
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
You’ll get:
- Dexamethasone – Group 1 only - A pill that you take by mouth or given as intravenous (IV) infusions
- Elotuzumab – Group 2 only - Given as IV infusions
- Linvoseltamab - Group 1 only - Given as IV infusions The number of doses you'll get depends on when you start the trial and how safe it has been
- Pomalidomide - Group 2 only - A pill that you take by mouth
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has dexamethasone, elotuzumab and pomalidomide for the treatment of multiple myeloma. The FDA has not yet approved linvoseltamab.
Locations
Sponsors
lead: Regeneron Pharmaceuticals
